Pediatric inflammatory bowel disease (IBD) patients have a relatively low risk of severe COVID-19, even when receiving biologic and other immune-suppressive therapies, according to an analysis of two international databases. This analysis also shows that medication adherence is important.
Andrew B. Grossman, MD, from our Center for Pediatric Inflammatory Bowel Disease discusses the reassuring studies in this MedPageToday article.
Featured in this article
Specialties & Programs
Pediatric inflammatory bowel disease (IBD) patients have a relatively low risk of severe COVID-19, even when receiving biologic and other immune-suppressive therapies, according to an analysis of two international databases. This analysis also shows that medication adherence is important.
Andrew B. Grossman, MD, from our Center for Pediatric Inflammatory Bowel Disease discusses the reassuring studies in this MedPageToday article.
Contact us
Joey McCool Ryan
Center for Pediatric Inflammatory Bowel Disease